BYSI

Phase 2 Study Results: BeyondSpring Inc. presented phase 2 data on their cancer therapy plinabulin combined with pembrolizumab and docetaxel for non-small cell lung cancer (NSCLC) at the SITC Annual Meeting, showing a confirmed overall response rate of 21.1% and a median progression-free survival of 8.6 months among treated patients.

Study Overview and Mechanism: The ongoing study, conducted in Beijing, aims to evaluate the efficacy and safety of this triple combination in patients who have progressed after previous treatments, highlighting plinabulin's unique mechanism of enhancing dendritic cell maturation to potentially overcome resistance to immune checkpoint inhibitors.

Dublin-3 Study Findings: BeyondSpring Inc. presented final data from the Dublin-3 study at ESMO Congress 2024, showing that the combination of plinabulin and docetaxel significantly improved overall survival and reduced severe neutropenia in patients with EGFR wild-type NSCLC compared to docetaxel alone.

Safety and Quality of Life Improvements: The combination therapy was well tolerated, with fewer grade 4 treatment-emergent adverse events and a notable improvement in quality of life, suggesting it could be a new treatment option for patients who have not responded to standard therapies.

SEED-Eisai Collaboration: SEED Therapeutics has entered a strategic research collaboration with Eisai Co., Ltd. to develop novel molecular glue degraders for neurodegeneration and cancer, with potential financial benefits of up to $1.5 billion in milestone payments and royalties.

Series A-3 Financing: SEED has initiated Series A-3 financing, raising $24 million led by Eisai, aimed at advancing clinical development of its cancer programs and expanding its targeted protein degradation platform, with further funding expected in Q4 2024.